Results 11 to 20 of about 23,377,083 (210)
PLoS ONE, 2012 BACKGROUND: A given tumor is usually dependent on the oncogene that is activated in the respective tumor entity. This phenomenon called oncogene addiction provides the rationale for attempts to target oncogene products in a therapeutic manner, be it by ...
Frank M Lehmann +9 more
doaj +8 more sources
Translocations involving c-myc and c-myc function [PDF]
Oncogene, 2001 c-MYC is the prototype for oncogene activation by chromosomal translocation. In contrast to the tightly regulated expression of c-myc in normal cells, c-myc is frequently deregulated in human cancers. Herein, aspects of c-myc gene activation and the function of the c-Myc protein are reviewed.
L M, Boxer, C V, Dang
openaire +2 more sources
Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation [PDF]
Oncogene, 1997 Using an extensive series of deletion and site-specific mutation constructs, we have identified five new phosphorylation sites in c-Myc in the N-terminal transactivation domain and near the C-terminal DNA binding/heterodimerization domain. We have also found that Thr-58 phosphorylation is regulated by specific cellular events.
B, Lutterbach, S R, Hann
openaire +2 more sources
Apoptotic signaling by c-MYC [PDF]
Oncogene, 2008 c-MYC has a pivotal function in growth control, differentiation and apoptosis, and its abnormal expression is associated with many tumors. Overexpression of c-MYC sensitizes cells to apoptosis by a variety of stimuli. The decision of a cell to undergo apoptosis and how this apoptotic response is regulated by c-MYC depends on the specific cell type and ...
B, Hoffman, D A, Liebermann
openaire +2 more sources
Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis [PDF]
, 2004 Background Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes.
Abouna, Sylvie +11 more
core +1 more source
Runx transcription factors repress human and murine c-Myc expression in a DNA-binding and C-terminally dependent manner. [PDF]
PLoS ONE, 2013 The transcription factors Runx1 and c-Myc have individually been shown to regulate important gene targets as well as to collaborate in oncogenesis. However, it is unknown whether there is a regulatory relationship between the two genes. In this study, we
Paejonette T Jacobs +6 more
doaj +1 more source
Physiological roles of the oncoprotein c-Myc in mouse mammary gland development [PDF]
, 2009 c-Myc, a transcription factor that affects a large number of target genes, is one of the most frequently deregulated oncoproteins in human cancer. The wide-ranging biological functions of c-Myc include regulation of the cell cycle, differentiation ...
Stölzle, Tina
core +1 more source
Sequential and coordinated actions of c-Myc and N-Myc control appendicular skeletal development. [PDF]
PLoS ONE, 2011 BACKGROUND: During limb development, chondrocytes and osteoblasts emerge from condensations of limb bud mesenchyme. These cells then proliferate and differentiate in separate but adjacent compartments and function cooperatively to promote bone growth ...
Zi-Qiang Zhou +5 more
doaj +1 more source
Targeting of the MYCN protein with small molecule c-MYC inhibitors [PDF]
, 2014 This study was funded by grants from the Swedish Research Council and the Swedish Cancer Society. IM and HZ were recipients of graduate student grants from KI (KID), MAH was recipient of a Senior Investigator Award from the Swedish Cancer Society, and ...
Edward V Prochownik +44 more
core +2 more sources
c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer. [PDF]
PLoS ONE, 2015 The aim of this study was to determine the incidence and clinicopathological significance of c-MYC gene copy-number (GCN) gain in patients with primary colorectal cancer (CRC).The c-MYC GCN was investigated in 367 consecutive CRC patients (cohort 1) by ...
Kyu Sang Lee +7 more
doaj +1 more source